- 1 Title page
- 2 Genetic liability to sedentary behavior increases the risk of cardiovascular
- 3 disease incidence: Evidence from the FinnGen cohort with 293,250
- 4 individuals
- 5 Joensuu L.<sup>1</sup>\*, Koivunen K.<sup>1</sup>, Tynkkynen N.<sup>1</sup>, Palviainen T.<sup>2</sup>, Kaprio J.<sup>2</sup>, FinnGen, Klevjer
- 6 M.<sup>3,4</sup>, Øvretveit K.<sup>5</sup>, Wisløff U.<sup>3</sup>, Bye A.<sup>3,4</sup>, Ekelund U.<sup>6,7</sup>, Sillanpää, E.<sup>1,8</sup>.
- <sup>1</sup>Gerontology Research Center, Faculty of Sport and Health Sciences, University of
- 8 Jyväskylä, Jyväskylä, FINLAND; <sup>2</sup>Institute for Molecular Medicine Finland, HiLIFE,
- 9 University of Helsinki, Helsinki, FINLAND; <sup>3</sup>Cardiac Exercise Research Group, Department
- of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, Norwegian
- 11 University of Science and Technology, Trondheim, NORWAY; <sup>4</sup>Clinic of Cardiology, St.
- 12 Olav's Hospital, Trondheim, NORWAY; <sup>5</sup>HUNT Center for Molecular and Clinical
- 13 Epidemiology, Department of Public Health and Nursing, Norwegian University of Science
- and Technology, Trondheim, NORWAY; <sup>6</sup>Norwegian School of Sport Sciences, Oslo,
- NORWAY; <sup>7</sup>Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo,
- NORWAY; <sup>8</sup>Wellbeing Services County of Central Finland, Jyväskylä, FINLAND
- 17 Correspondence to:
- \*Laura Joensuu, laura.p.joensuu@jyu.fi, +358504363466, Faculty of Sport and Health
- 19 Sciences, University of Jyväskylä PO Box 35, FI-40014 Jyväskylä, Finland
- 20 Running title: Genetic sedentarism and cardiovascular disease
- 21 Total word count: 7811

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

**Abstract Background** It is unclear how the genetics of sedentary behavior are associated with incident cardiovascular disease (CVD). We investigated the associations between genetic liability to sedentary behavior, sedentariness, and four main CVD outcomes: any CVD, hypertensive diseases, ischemic heart diseases, and cerebrovascular diseases. Methods Leisure screen time was used as a proxy for sedentary behavior. We developed a polygenic score for leisure screen time (PGS LST) based on over 890,000 genetic variants. We tested the validity of this score against self-reported LST in the older Finnish Twin Cohort (FTC, N=2,689, mean age of 60.5±3.7 years, 54.7% women) using linear regression. We examined the associations between PGS LST and register-based records of CVDs using survival models among FinnGen participants (N=293,250–333,012, 67.0±13.0 years at follow-up, 52.3% women). We replicated analyses in an independent cohort (Trøndelag Health Study [HUNT], N=35,289, 64.0±13.1 years, 51.6% women) and explored if the associations persist following adjustments for socioeconomic status, body mass index, and smoking or are mediated via reduced physical activity. **Results** In the FTC, each standard deviation increase in PGS LST was associated with greater selfreported LST (hours/day) ( $\beta = 0.09, 95\%$  CI: 0.05–0.14). In FinnGen, each standard deviation increase in PGS LST was associated with a higher risk of incident CVD (hazard ratio: 1.05, [1.05–1.06]) (168,770 cases over 17,101,133 person-years). The magnitudes of association for three most common CVDs were 1.09 (1.08–1.09), 1.06 (1.05–1.07), and 1.05 (1.04–1.06) for hypertensive diseases, ischemic heart diseases, and cerebrovascular diseases,

respectively. Those in the top decile of PGS LST had 21%, 35%, 26%, and 19% higher risk

- of any CVD, hypertensive diseases, ischemic heart diseases, and cerebrovascular diseases,
- 48 respectively, than those in the bottom decile. Associations replicated in HUNT and remained
- 49 independent of covariates except for cerebrovascular diseases. Besides direct effects, reduced
- 50 physical activity served as a potential mediating pathway for the associations.
- 51 Conclusions
- A higher genetic liability to sedentary behavior is associated with a greater risk of developing
- 53 CVDs, although effect sizes with current PGS remain small. Our findings suggest that genetic
- 54 liability to sedentary behavior is an underrecognized driver of common CVDs.

Clinical perspective

What is new?

55

60

61

62

67

68

- It is not known whether a genetic liability to sedentary behavior is a mutual underlying factor for both sedentary behavior and incident cardiovascular disease at the population level.
  - We observed that a higher polygenic score for leisure screen time was associated with more self-reported leisure screen time and a higher risk of common cardiovascular diseases.
- What are the clinical implications?
- This study provides novel insights into the relationship between genetic

  predisposition to sedentary behavior and the development of cardiovascular diseases,

  shedding light on a previously underexplored aspect of disease etiology.
  - These results may motivate health professionals to encourage sedentary persons to undertake at least some physical activity.

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

Introduction Cardiovascular diseases (CVDs) are the leading cause of disease burden and death worldwide. Sedentary behavior is any waking behavior in a sitting, reclining, or lying posture and characterized by an energy expenditure of less than or equal to 1.5 metabolic equivalents.<sup>2</sup> Adults spend up to 60% of their awake time sedentary.<sup>3</sup> The prevalence of sedentary behaviors has remained stable or even increased during the last 20 years.<sup>4</sup> Sedentary behaviors are systematically associated with increased risk of CVD incidence and related mortality in prospective observational cohort studies.<sup>5,6</sup> Interestingly, energy-saving sedentary behavior has been suggested to be a trait selected by evolution to ensure reproduction and survival.<sup>7</sup> Thus, genetics may be an important driver of sedentary behavior, as supported by previous evidence from twin and candidate gene studies. <sup>8</sup> However, the potential effects of this genetic liability on morbidity are unclear. From an evolutionary perspective, it is plausible that genetic predisposition to sedentary behavior increases the risk of common non-communicable diseases. 9,10 It has been suggested that the rapid environmental changes in societies, particularly in Western countries, may have led to an "evolutionary mismatch". In this scenario, the previously advantageous alleles, e.g. the genetic liability for sedentary behavior, may cause morbidity in the current post-industrial environment. 11 Furthermore, as life expectancy has increased, the deleterious effects of underlying genetics may become more apparent. 10 The theory of antagonistic pleiotropy suggests that some genes that have favored survival during reproductive ages in the past may currently limit lifespan and increase morbidity. 12 Underlying genetics may therefore be an important confounding factor in the commonly observed associations between sedentary behavior and incident CVD.

Polygenic scores (PGSs) summarize the genome-wide information between single-nucleotide

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

polymorphisms (SNPs) and a phenotype into a single variable that quantifies a person's genetic liability for a given trait.<sup>13</sup> In this study, we assess whether a higher genetic liability for sedentary behavior is associated with an increased risk of incident CVD at the population level. Leisure screen time (LST) is a commonly reported voluntary mode of sedentary behavior and thus serves as a proxy for this trait. We hypothesized that higher genetic liability for LST, as measured by a polygenic score (PGS LST), is associated with an increased risk of developing a CVD. **Methods** This study consists of four phases. First, we constructed a PGS for LST. Second, we assessed the validity of this score against self-reported LST in the older Finnish Twin Cohort (FTC). Third, we assessed the associations between the PGS LST and incident CVD in the FinnGen cohort (~10% of the Finnish population). Finally, we replicated the analyses in an independent cohort (The Trøndelag Health Study [the HUNT study]). The study design and cohorts are shown in Figure 1. Additionally, we conducted exploratory analyses to estimate the potential explanations for the observed associations. Study cohorts Base data for PGS LST. We used the publicly available genome-wide association study (GWAS) summary statistics previously published by Wang et al. (2022) as the base data for PGS LST calculation. The data included 526,725 genotyped individuals from 24 different cohorts with European ancestry (mean age of  $49.5 \pm 7.6$  years). For more information regarding the base data, please see Table S1. Validation cohort. The FTC is a prospective population-based cohort study that began in 1975 and has provided a 50-year follow-up resource for genetic epidemiology. The study

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

details have been described elsewhere, but briefly, all same-sex twins born before 1958 and residing in Finland were invited to participate in the study. 14 The majority of the invitees accepted (response rate of 84.4%, N = 31,145). In this study, we used a genotyped subsample of the FTC who completed a questionnaire on their sedentary behavior in 2011 (N = 2,689, mean age of  $60.5 \pm 3.7$  years, 54.7% women) (Table S2). Main cohort. FinnGen is a public–private partnership research project linking genotype and digital health record data from Finnish health registries using unique national personal identification numbers. The FinnGen data release 11 comprises 520,210 biobank participants (https://www.finngen.fi/en). 15 The biobanks include regional, hospital-based biobanks (Auria Biobank, Biobank of Central Finland, Biobank of Eastern Finland, Borealis Biobank, Helsinki Biobank, Tampere Biobank), the Blood Service Biobank, the Terveystalo Biobank, and the Finnish Institute for Health and Welfare (THL) Biobank, which includes phenotypic and genetic information from the following studies: Botnia, Corogene, FinHealth 2017, FinIPF, FINRISK 1992–2012, GeneRisk, Health 2000, Health 2011, Kuusamo, Migraine, Super, T1D, and Finnish Twin Cohort. In our study, we excluded participants under the age of 40 years at the end of the follow-up. This was done to focus on a more homogenous adult population and CVDs, which develop over time. This process resulted in a sample of 293,250 participants for incidence of any CVD. We used the same criteria to obtain samples for the three most prevalent CVDs in the FinnGen, with 322,890 participants for hypertensive diseases, 333,012 for ischemic heart diseases, and 332,730 for cerebrovascular diseases. The larger sample sizes for the three most common CVDs result from their later onset in life compared to all potential CVD diagnoses. Replication and exploratory cohort. The HUNT study is conducted in the Trøndelag region of Norway. It commenced in 1984, inviting all residents 20 years old and above in the former

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

county of Nord-Trøndelag, now Trøndelag, to participate. To date, a total of four surveys have been completed: HUNT1 (1984–1986, N = 77,202, 89.4% participation rate), HUNT2 (1995–1997, N = 65,228, 69.5% participation rate), HUNT3 (2006–2008, N = 50,800, 54.1% participation rate), and HUNT4 (2017–2019, N = 56,04, 54.0% participation rate). <sup>16</sup> The study data include laboratory measurements, questionnaires, interviews, and clinical examinations performed by trained personnel. More information about HUNT is available on the project's website (ntnu.edu/hunt). In this study, we used a subsample of individuals from HUNT2 and HUNT3 with available genotype and health record data (N = 35,289). Ethical considerations The base data for PGS LST were published in the National Human Genome Research Institute-European Bioinformatics Institute GWAS Catalog. The catalog follows the General Data Protection Regulation applicable from 25 May 2018.<sup>17</sup> The different processes of the FTC study and data pooling have been evaluated by ethics committees of the University of Helsinki (113/E3/01 and 346/E0/05), Helsinki University Central Hospital (136/E3/01, 01/2011, 270/13/03/01/2008, 154/13/03/00/2011, HUS/1799/2017), and the Finnish Institute for Health and Welfare (THL/4743/6.02.04/2021). The FinnGen cohort consists of participants from Finnish biobanks. Participants in FinnGen provided informed consent for biobank research on the basis of the Finnish Biobank Act. Alternatively, separate research cohorts, collected before the Finnish Biobank Act came into effect (September 2013) and the start of FinnGen (August 2017), were collected based on study-specific consent and later transferred to the Finnish biobanks after approval by Fimea, the National Supervisory Authority for Welfare and Health. Further information related to ethical procedures and permits in the FinnGen study are provided in the Supplemental Material (under Supplemental Methods, page 2). The HUNT study was approved by the Regional Committee for Medical and Health Research Ethics (REC; 2019/29771), the Trøndelag Health Study, the Norwegian

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

Data Inspectorate, and the National Directorate of Health. All participants provided written informed consent. The authors assume responsibility for the accuracy and completeness of the protocol, data, and analyses, fidelity of their reporting, and compliance with the Declaration of Helsinki, national laws, and guidelines of the Finnish Advisory Board on Research Integrity. **Outcomes** LST. For the validation analyses in the FTC, LST in hours per day (h/day) was used as the outcome and included self-reported television and video viewing and computer use at home. This outcome was selected to match exactly the outcome used in the base data for PGS LST. In the FTC, participants reported how many hours per day they spent sitting: at home watching TV or videos and at home at the computer. Each question had four choices: (a) less than an hour, (b) an hour–less than two hours, (c) two hours–less than four hours, and (d) four hours or more. 18 Answers were summarized to indicate LST (h/day). The data were collected in 2011 and represent screen time activities at that time. CVD. The CVD categorization was based on FinnGen endpoint definitions. The following ICD-10 codes (ICD-9 codes [and FinnGen labels]) were used: All CVDs, I00-I99, T82.2, Z95.1 (390-459, 4019X, 4029A, 4029B, 4039A, 4040A, 4059A, 4059B, 4059X, 4160A, 4330A, 4330X, 4331A, 4331X, 4339A, 4339X, 4340A, 4341A, 4349A, 4371, 4372, 4372A, 4373, 4374, 4375, 4376, 4378X, and 9960A [I9\_CVD]); Hypertensive diseases, I10-I15, I27.0, I67.4 (4019X, 4029A, 4029B, 4039A, 4040A, 4059A, 4059B, 4059X, 4160A, and 4372A [I9 HYPERTENSION]), Ischemic heart diseases, I20-I25, T82.2, Z95.1 (410, 411[0-1], 412, 413, 414, 9960A [I9 ISCHHEART]), and Cerebrovascular diseases, I60-I69 (430, 431, 436, 438, 4330A, 4330X, 4331A, 4331X, 4339A, 4339X, 4340A, 4341A, 4349A, 4371, 4372, 4373, 4374, 4375, 4376, and 4378X [I9\_CEREBVASC]). The register data were based

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

on the national hospital discharge (available from 1968) and causes of death (available from 1969) registers. Additionally, any CVDs included data from Care Register for Health Care for coronary angioplasty, coronary artery bypass, valvular operations, endovascular or surgical operations to intracerebral aneurysms, and peripheral artery operations and from the Finnish Social Insurance Institution drug reimbursement register for atrial fibrillation and flutter, heart failure, and hypertension. Hypertensive diseases also included data from the drug reimbursement register. Further descriptive information, such as disease prevalence and age distribution, can be queried using FinnGen labels via the Risteys interface (risteys.finregistry.fi). We utilized the same ICD-10 and ICD-9 codes in the HUNT replication analyses. The HUNT health records are based on the Nord-Trøndelag Health Trust discharge register (available from 1987). Exposure The PGS LST was based on the largest available GWAS meta-analysis for LST at the time of the analysis (GWAS Catalog Study ID: GCST90104339). In this data, the LST included self-reported television viewing, video game playing, and computer use at home. The discovery data reportedly explained 2.8% of the variance in self-reported LST, <sup>19</sup> and the SNP heritability was 7.4%.<sup>20</sup> The base data did not overlap with the later used FTC, FinnGen or HUNT study cohorts. We used the high-performing SbayesR approach to construct the PGS.<sup>21</sup> In SbayesR, the base data summary statistics are re-weighted to consider the linkage disequilibrium between each variant and restricted to HapMap3 SNPs to ensure computational efficiency while representing the whole genome. The pipeline and relevant codes are available elsewhere.<sup>22</sup> The final number of processed variants was 890,575 in the FTC, 891,628 in the FinnGen cohort, and 901,640 in the HUNT cohort. We used standardized PGS LST scores (mean of

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

zero, standard deviation of one) in the analyses. The PGS LST fitted well to the FTC, FinnGen, and HUNT cohorts and followed a normal distribution. Genotyping, quality control, and imputation In the FTC, chip genotyping was done using Illumina Human610-Ouad v1.0 B, Human670-QuadCustom v1.0 A, Illumina HumanCoreExome, and Affymetrix FinnGen Axiom arrays. Genotype quality control was done in three batches (batch1: 610k+670k chip, batch2: HumanCoreExome, and batch3: Affymetrix chip genotypes), and genotypes of all batches were imputed to the Haplotype Reference Consortium release 1.1 reference panel.<sup>23</sup> More details related to genotyping procedures in the FTC are available in the Supplemental Material (Supplemental Methods, page 2). The FinnGen samples were genotyped with Illumina and Affymetrix chip arrays (Illumina Inc., San Diego, and Thermo Fisher Scientific, Santa Clara, CA, USA). A detailed information on genotyping, quality control, and imputation has been described elsewhere: https://finngen.gitbook.io/documentation/. In the HUNT study, a total of ~69,000 participants contributed with DNA for genotyping in HUNT2 and HUNT3. Detailed information on genotyping, imputation, and quality control is described in more detail elsewhere.<sup>24</sup> **Covariates** Covariates were based on previous literature. <sup>25,26</sup> The first ten principal components of ancestry adjust for any genetic stratification that may occur in the study population and were used alongside with sex as a covariate in all analyses.<sup>25</sup> Additional covariates were specific to the analysis. In validation analyses in the FTC, we also used age, educational attainment (highest achieved self-reported educational degree in the Finnish educational system; low,

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

basic education degree at most; middle, basic education and additional studies; and high, at least upper secondary degree),<sup>27</sup> and body mass index (BMI) based on valid self-reported height and weight.<sup>28</sup> In main and replication analyses, we also used genotyping batch, which accounts for the potential stratification that may occur form the genotyping array and sample. In further exploratory analyses with the replication cohort, we controlled for variance caused by highly plausible covariates, such as BMI (based on measured height and weight [Jenix DS-102, Dong Sahn Jenix Co, Ltd, Korea]), socioeconomic status (SES; derived from occupational status),<sup>26</sup> and self-reported smoking status (never, former, current) using the HUNT3 data. Statistical analysis Validation analyses. All validation analyses were performed with Stata (StataCorp, College Station, TX, USA). Correlation between PGS LST and self-reported LST was tested with Pearson correlation. The association between PGS LST and self-reported LST was assessed with linear regression in the FTC, where the twin structure of the data was acknowledged using the syyset command (i.e., the twin pair was the primary sampling unit). The crude model included standardized PGS LST and the first ten principal components of ancestry. Model 1 was adjusted additionally for age and sex, and Model 2 was further adjusted with educational attainment and BMI. Differences between high and low genetic liabilities were evaluated using linear regression, where a binary variable indicated whether the individual belonged to the highest or lowest decile of PGS LST. A priori power calculations indicated that sufficient statistical power would be reached with a sample size of N > 950 (expected small effect size 0.02, 15 predictors, power at 0.8 level, and  $\alpha$  set to 0.05). Main analyses. We used Cox proportional hazard models and R packages survival<sup>29</sup> and survminer<sup>30</sup> to estimate the hazard ratios (HRs) and 95% confidence intervals (CI) between

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

PGS LST and incident CVD in the FinnGen cohort. Visual inspection of Schoenfeld residuals and log-minus-log plots indicated that the finally adjusted models satisfy the proportional hazard assumptions.<sup>31</sup> PGS×SEX interaction was tested, but no replicable sex differences were observed; thus, analyses were conducted for men and women in combination. We used age as the time scale and the first ten principal components of ancestry, genotyping batch, and sex as covariates. Start of follow-up was set at birth, as the PGS remains stable from conception. Follow-up ended with whichever came first among the first record of the endpoint of interest, death, or the end of follow-up on 31 December 2021. Utilizing the weights of the European standard population, age-standardized incidence was calculated when relevant.<sup>32</sup> We also compared the hazard ratios (relative measures of survival) and cohort-specific cumulative incidence of events (absolute measures of survival) between the highest and lowest deciles of PGS LST. We additionally conducted competing risk analysis with Fine-Gray sub-distribution hazard models for the three main CVDs, as one event may preclude the occurrence of another. Here, we coded censored as "0," events of interest as "1," and other competing CVD events as "2". 33 Additionally, as the exposure (PGS LST) might affect who survives until genotyping and also to control for immortal time bias, we conducted sensitivity analyses in which the start of the follow-up was set to the date of individual DNA sampling. Sufficient statistical power was expected to be achieved with > 120 cases, using a classical definition of 10 cases per predictor variable. Replication analyses. The replication analyses were conducted in HUNT and followed a similar procedure as the main survival analyses, except that when mortality data were not available, the end of follow-up was assigned to whichever came first between the first record of the endpoint of interest and last verified contact with healthcare. Exploratory analyses. In HUNT, we also conducted several exploratory analyses to assess the

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

potential sources of observations in the main and replication analyses. We tested if the associations were independent of highly plausible covariates with a complete case subsample of HUNT3. In this analysis, Model 1 included PGS LST, the first ten principal components of ancestry, sex, and genotyping batch while Model 2 included additionally SES, Model 3 additionally BMI, and Model 4 additionally smoking status. We also tested a potential mediating pathway from PGS LST to incident CVD via sedentary behavior using the product of coefficients approach and accompanying Sobel test, which are suitable for survival analysis with common outcomes.<sup>34</sup> In this mediation analysis, we used participants from the sensitivity analyses with self-reported total sitting time (h/day): "About how many hours do you sit during an average day? (include work hours and leisure time)". Only diseases for which a direct association between PGS LST and incident disease was observed in the sensitivity analyses were included in the mediation analysis. Association between PGS LST and total sitting time were evaluated with linear regression, while a Cox proportional hazards model was used for the association between total sitting time and disease incidence. The models were adjusted for sex similar to prior sensitivity analyses but not for the first ten principal components or genotyping batch for consistency across pathways. These mediating analyses were replicated with a physical activity variable, i.e., metabolic equivalent (MET) hours per week, calculated as the product of self-reported physical activity frequency, intensity, and duration. Across all analyses, all tests were two-tailed, and  $\alpha$  was set at p < 0.05. **Results** Association between polygenic score for leisure screen time and self-reported leisure screen timeThe 2,689 individuals of the FTC reported an average of  $3.9 \pm 1.1$  hours LST per day (Table S2). The effect size for PGS LST against LST was small (Pearson correlation coefficient =

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

0.08, p < 0.001), and PGS LST explained 0.7% of the variance in the LST. PGS LST of one standard deviation higher was associated with higher self-reported LST (h/day), with  $\beta = 0.09$ (95% CI: 0.05–0.14) in crude models;  $\beta = 0.09$  (95% CI: 0.05–0.13) after adjustments for age, and sex; and  $\beta = 0.08$  (95% CI: 0.04–0.13) after further adjustments for educational attainment and BMI (Table S3). Correspondingly, individuals in the highest decile for PGS LST reported an average of  $4.1 \pm 1.0$  h/day LST, while those in the lowest decile reported an average of 3.7 (1.1) h/day (p < 0.001 for difference) (Table S4). Association between polygenic score for leisure screen time and cardiovascular disease incidence Descriptive data on 293,250 participants in the FinnGen sample of any CVD are shown in Table 1. Fifty-eight percent in the FinnGen cohort were diagnosed with a CVD in adulthood  $(\ge 40 \text{ years old}, 168,770 \text{ cases})$  with an age-standardized incidence of 34.9 per 10,000 person-years (Figure 2). The average follow-up time from birth was 58 (40 to 106) years, with a total of 17,101,133 person-years. The descriptives of 35,289 participants in the HUNT replication cohort are presented in Table 1. The age-standardized incidence for any CVD was 36.5 per 10,000 person-years (Figure 2), with an average follow-up time of 64 (40 to 103) years and a total of 2,257,493 person-years. In FinnGen, PGS LST of one standard deviation higher was associated with a higher risk of any CVD after adjusting for the first ten principal components of ancestry, sex, and genotyping batch (HR: 1.05, 95% CI: 1.05–1.06; Figure 2). Disease-specific associations for three most common CVDs were 1) 1.09 (1.08 – 1.09) for hypertensive diseases (108,040 cases), 2) 1.06 (1.05 - 1.07) for ischemic heart diseases (64,724 cases), and 3) 1.05 (1.04 -1.06) for cerebrovascular diseases (34,170 cases). The associations were replicated in the HUNT cohort with exactly or very similar effect sizes (Figure 2).

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

In the FinnGen cohort, those in the highest PGS LST decile had 19% to 35% higher risk of CVDs compared to those in the lowest PGS LST decile (Table S5). For example, at 60 years of age, the cumulative incidence for any CVDs was 44% for those with high PGS LST, while for those with low PGS LST it was 37% (Table S7, Figure 3). This higher risk of incident CVD in participants with higher genetic liability replicated in HUNT, except for cerebrovascular disease (HR: 1.08 [0.96–1.20]) (Table S6, Figure S1). Considering other CVDs as competing events attenuated the cumulative incidence estimates for both high and low PGS LST participants, but their difference remained statistically significant for hypertensive diseases and ischemic heart diseases, although not for cerebrovascular diseases (Table S8). In further sensitivity analyses with follow-up starting from individual DNA sampling dates (mean follow-up was 6.0 years in FinnGen and 5.0 in HUNT), the associations remained the same or were slightly attenuated in the FinnGen cohort, and replicated in the HUNT cohort except for any CVD and cerebrovascular diseases (Table S9). Exploratory analyses showed that the association between PGS LST and incident CVD persisted after adjustments for SES, BMI, and smoking status, except for cerebrovascular diseases, where the number of cases was smallest (Figure S2). Mediation analysis showed that higher PGS LST was associated with higher self-reported total sitting time (h/day) in the HUNT cohort ( $\beta = 0.06$ , standard error [SE] = 0.02, p = 0.016 in a model for hypertensive diseases and  $\beta = 0.07$ , SE = 0.02, p = 0.003 for ischemic heart diseases) but indicated no potential mediating pathway to incident CVD (Figure S3). However, higher PGS LST was also associated with lower MET h/week ( $\beta = -0.54$ , SE = 0.09, p < 0.001 for hypertensive diseases and  $\beta = -0.47$ , SE = 0.09, p < 0.001 for ischemic heart diseases), while higher MET h/week was associated with lower risk of hypertensive and ischemic heart diseases ( $\beta = -0.01$ ,

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

SE = 0.00, p < 0.001 and  $\beta$  = -0.01, SE = 0.00, p = 0.005, respectively), thus indicating a potential mediating pathway through reduction in physical activity. **Discussion** We found that higher genetic liability to LST was associated with more self-reported LST and that the genetic liability to LST also increased the risk of incident CVD, with replicable findings across two independent large populations. The observed effect sizes remained relatively small and attenuated after adjustment, but suggest that the observed adverse health effects may be either directly attributable to genetic effects or mediated by reduced levels of physical activity. The underlying role of genetics in sedentary behavior and morbidity has so far been understudied. Evolution has a profound influence on human biology; hence, evolution-based theories provide valuable insights into epidemiology and population health. Evolutionary selection processes may explain why the "desire to be sedentary is in our genes" and also why previously advantageous alleles may currently be disease-causing alleles. 9,10,35 In our study, the risk of any CVD increased very consistently by 5% per standard deviation increase in the PGS LST. Furthermore, we observed that the risk of CVD differs significantly between those in the highest and lowest deciles of PGS LST. Those with high PGS LST had 21% (19% to 24%) higher risk for any CVD than those with low PGS LST. Those with high PGS LST also indicated higher cumulative disease incidences at different ages, therefore showing lower probability for survival. For example, at the age of 60, those with a high PGS LST had a 7% higher cumulative incidence for any CVD compared to those with a low PGS LST. The associations were statistically independent of SES, BMI, and smoking, although adjustment for these factors attenuated the associations. One explanation for these findings may be genetic pleiotropy.

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

In genetic pleiotropy, the same genes would affect both LST and CVD. This theory is supported by previously published genetic correlations between LST and several CVDrelated phenotypes (0.24 for coronary artery disease, 0.32 for overweight, 0.22 for type 2 diabetes, -0.26 for high-density lipoprotein cholesterol, and 0.27 for triglycerides), indicating shared genetic material. 19 Previous studies suggest that most robust pleiotropic genes are associated with function of the nervous system, e.g., the DLG4 gene (ENSG00000132535) is associated with synaptic function in the brain, pituitary gland, and retina. <sup>36,37</sup> Overall, the tissue enrichment analyses suggest that currently known genes associated with LST are expressed mainly in the nervous system, specifically in the brain. <sup>19</sup> However, more studies are needed to further elucidate the underlying mechanism between genetic predisposition to LST and the onset of CVDs. Our mediation analysis suggests that there may also be an alternative pathway in which sedentary genes contribute to inadequate levels of physical activity, thereby increasing the risk of incident CVD. Much has been written about the benefits of physical activity on cardiovascular health, 38 with our findings bringing new perspectives to this discussion. The planning and implementation of public health interventions in different settings (e.g., schools, workplaces, communities) will benefit from an understanding of the inherent biological tendencies of the population.<sup>39</sup> Considering that genetics contribute to sedentary behavior, effective strategies should emphasize environmental planning that nudges people to be active and/or interventions that significantly nourish the intrinsic reward system. 40 Moving from sedentary to active behavior may confer health benefits, as the human evolutionary background may also explain why physiological functions operate optimally under regular physical activity.<sup>41</sup>

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

The observed coefficient of determination and effect size between PGS LST and selfreported LST were small, thus potentially raising concerns how well the score reflects genetic liability to this trait. As there is little prior evidence on how PGSs are associated to sedentary behavior while some data are available for physical activity, we discuss our findings aligned to this construct. Our results are consistent with previous studies in which physical activity PGSs were associated with the corresponding trait and differentiated well the extreme ends of the genetic spectrum, but explain only a small proportion (0.0–1.4%) of the phenotypic variance. 26,42 This is an interesting contrast and may suggest that current PGSs are not fully able to quantify all the genetic effects they detect. A plausible explanation for the small variances were assumed to be the heterogeneity in phenotype assessment (i.e., physical activity collected through varying methods). However, in our study, we carefully selected the validation data to mimic the phenotype in the base data. Nevertheless, the fraction of variance explained remained small and may indicate other methodological limitations related to polygenic scoring. One of these is the "missing heritability" dilemma. Missing heritability is the difference between the observed SNP heritability and heritability estimates based on twin studies. In our case, this is estimated to be at least 22% <sup>43–45</sup> and potentially caused by the following: inflated family-based estimates, <sup>46</sup> relatively small sample sizes of current GWASs, <sup>47</sup> inadequate accuracy in phenotyping of the trait of interest, and/or the lack of information on less common and rare variants in genotyping arrays used in GWAS studies. More detailed coverage of the variation in the genome by whole genome sequencing is expected to reduce missing heritability. 48,49 **Strengths and limitations** This study has several strengths. We used high-performing and genome-wide methods for genetic scoring and showed the scores to be valid with independent data sets. We used the most comprehensive data available and a robust study design, which included a replication

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

cohort. We further tested the robustness of our findings with multiple approaches, with consistent findings supporting our conclusions. We also acknowledge that our results should be interpreted with the following limitations in mind. The base data for PGS LST is based on self-reported LST which may be subject to biases from recall, cultural differences, and social desirability.<sup>50</sup> Notably, the LST represented screen time activities at the time of the data collection (2011) with limited generalizability to the modern era. The ability to replicate genetic variants related to LST across cohorts remains a challenge, and more quality GWASs regarding sedentary behavior are required.<sup>36</sup> The data were based on individuals with European ancestry. Hence, replication studies using other populations are required. The FinnGen did not have data related to sedentary behavior or physical activity, and therefore, the mediation analyses could not be conducted in this cohort. The used FinnGen and HUNT may be enriched with CVDs due to participants having had an established contact with healthcare services. **Conclusions** The findings of this study confirm our hypothesis that higher genetic liability for sedentary behavior is associated with a greater risk of developing CVD, although effect sizes with the current data and methods remain small. Acknowledgements We thank the participants and all those who contributed to the data collection from the FTC, FinnGen, and HUNT cohorts without whom this study would not be possible. The detailed list of investigators involved in the FinnGen is available on page 12 of the Supplemental Material.

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

Sources of Funding **Funding** The funders were not involved in planning, analyzing, or drafting the manuscript in any way. The study and FTC data collection were funded by the Research Council of Finland (grants 341750, 346509 and 361981 to ES, grants 265240, 263278, 100499, 205585, 118555, 141054, 264146, 308248, 312073, 336823, and 352792 to JK); the Juho Vainio Foundation to ES; the Päivikki and Sakari Sohlberg Foundation to ES; and the Sigrid Juselius Foundation, the Wellcome Trust Sanger Institute, the Broad Institute, and the European Network for Genetic and Genomic Epidemiology to JK. The FinnGen project is funded by Business Finland and thirteen international pharmaceutical industry partners: AbbVie, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene/Bristol-Myers Scibb, Genentech (a member of the Roche Group), GSK, Janssen, Maze Therapeutics, MSD/Merck, Novartis, Pfizer, and Sanofi. The HUNT study is a collaboration between HUNT Research Center (Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, NTNU), Trøndelag County Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Health. The genotyping in HUNT was financed by the National Institutes of Health; University of Michigan; the Research Council of Norway; the Liaison Committee for Education, Research and Innovation in Central Norway; and the Joint Research Committee between St. Olav's hospital and the Faculty of Medicine and Health Sciences, NTNU. The genetic investigations of the HUNT study are a collaboration between researchers from the KG Jebsen Center for Genetic Epidemiology, NTNU, the University of Michigan Medical School, and the University of Michigan School of Public Health. The KG Jebsen Center for Genetic Epidemiology is financed by Stiftelsen Kristian Gerhard Jebsen, Faculty of Medicine and Health Sciences, NTNU, Norway.

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

**Disclosures Competing interests.** The authors declare no competing interests. **Data sharing.** The utilized FTC subsample data are in the Biobank of the National Institute for Health and Welfare. Data are available for qualified researchers through a standardized application procedure (see the website https://thl.fi/en/web/thl-biobank/for-researchers for details). Access to individual-level genotypes and register data from FinnGen participants can be applied via the Fingenious portal (https://site.fingenious.fi/en/) hosted by the Finnish Biobank Cooperative FinBB (https://finbb.fi/en/). The register data also needs permission from FinData (www.findata.fi). Researchers affiliated with a Norwegian research institution can apply for HUNT data access from the HUNT Research Centre (www.ntnu.edu/hunt) if they have obtained project approval from the Regional Committee for Medical and Health Research Ethics (REC). Researchers not affiliated with a Norwegian research institution should collaborate with and apply through a Norwegian principal investigator. Information on the application and conditions for data access is available online (www.ntnu.edu/hunt/data). The HUNT Databank website provides a detailed overview of the available variables in HUNT (www.ntnu.edu/hunt/databank). Certain data from ancillary HUNT projects may be subject to a time-limited exclusivity provided to the researchers who have financed and conducted the data collection. Biological material is available for analyses, and information on procedures is found on the HUNT Biobank website (www.ntnu.edu/hunt/hunt-biobank). Data from the health registries are not kept by HUNT; instead, linkages between HUNT and registry data must be made for each research project and require that the principal investigator has obtained project-specific approval for such linkage from REC and each registry owner.

Contributorship LJ and ES conceptualized the research question, study design, and statistical analysis. KK, UE, and JK made significant contributions to the final analysis design. LJ prepossessed the polygenic score data under the supervision of TP and implemented the scores to the FTC, FinnGen, and HUNT study cohorts with the help of TP, KK, and NT. LJ performed the statistical modelling under supervision of ES and with consultation from NT. JK and TP participated in FTC data collection and management, while AB, MK, KØ, and UW to HUNT data. LJ drafted the first version of the manuscript, and all authors contributed significantly to the writing, critical interpretation of the findings, and revising the manuscript. ES acquired funding for the study. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

## References

512

- 513 1. Kyu HH, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, Abbastabar H, Abd-
- Allah F, Abdela J, Abdelalim A, et al. Global, regional, and national disability-adjusted
- life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE)
- for 195 countries and territories, 1990–2017: a systematic analysis for the Global
- 517 Burden of Disease Study 2017. *The Lancet*. 2018;392:1859–1922.
- 518 2. On behalf of SBRN Terminology Consensus Project Participants, Tremblay MS, Aubert
- 519 S, Barnes JD, Saunders TJ, Carson V, Latimer-Cheung AE, Chastin SFM, Altenburg
- 520 TM, Chinapaw MJM. Sedentary Behavior Research Network (SBRN) Terminology
- Consensus Project process and outcome. *Int. J. Behav. Nutr. Phys. Act.* 2017;14:75.
- 522 3. Husu P, Suni J, Vähä-Ypyä H, Sievänen H, Tokola K, Valkeinen H, Mäki-Opas T,
- Vasankari T. Objectively measured sedentary behavior and physical activity in a sample
- of Finnish adults: a cross-sectional study. *BMC Public Health*. 2016;16:920.
- 4. Yang L, Cao C, Kantor ED, Nguyen LH, Zheng X, Park Y, Giovannucci EL, Matthews
- 526 CE, Colditz GA, Cao Y. Trends in Sedentary Behavior Among the US Population,
- 527 2001-2016. *JAMA*. 2019;321:1587.
- 528 5. Biswas A, Oh PI, Faulkner GE, Bajaj RR, Silver MA, Mitchell MS, Alter DA.
- Sedentary Time and Its Association With Risk for Disease Incidence, Mortality, and
- Hospitalization in Adults: A Systematic Review and Meta-analysis. *Ann. Intern. Med.*
- 531 2015;162:123–132.
- 6. Ekelund U, Brown WJ, Steene-Johannessen J, Fagerland MW, Owen N, Powell KE,
- Bauman AE, Lee I-M. Do the associations of sedentary behaviour with cardiovascular
- disease mortality and cancer mortality differ by physical activity level? A systematic
- review and harmonised meta-analysis of data from 850 060 participants. Br. J. Sports
- 536 *Med.* 2019;53:886–894.
- 7. Raichlen DA, Lieberman DE. The evolution of human step counts and its association
- with the risk of chronic disease. Curr. Biol. 2022;32:R1206–R1214.
- 539 8. Young DR, Hivert M-F, Alhassan S, Camhi SM, Ferguson JF, Katzmarzyk PT, Lewis
- 540 CE, Owen N, Perry CK, Siddique J, et al. Sedentary Behavior and Cardiovascular
- Morbidity and Mortality: A Science Advisory From the American Heart Association.
- *Circulation* [Internet]. 2016 [cited 2024 Mar 19];134. Available from:
- 543 https://www.ahajournals.org/doi/10.1161/CIR.0000000000000440
- 544 9. Lea AJ, Clark AG, Dahl AW, Devinsky O, Garcia AR, Golden CD, Kamau J, Kraft TS,
- Lim YAL, Martins D, et al. Evolutionary mismatch and the role of GxE interactions in
- human disease. 2023 [cited 2023 Aug 28]; Available from:
- 547 https://arxiv.org/abs/2301.05255
- 548 10. Kirkwood TBL, Austad SN. Why do we age? *Nature*. 2000;408:233–238.
- 549 11. Manus MB. Evolutionary mismatch. Evol. Med. Public Health. 2018;2018:190–191.
- 550 12. Byars SG, Voskarides K. Antagonistic Pleiotropy in Human Disease. J. Mol. Evol.
- 551 2020;88:12–25.

- 552 13. Choi SW, Mak TS-H, O'Reilly PF. Tutorial: a guide to performing polygenic risk score 553 analyses. Nat. Protoc. 2020;15:2759-2772.
- 554 14. Kaprio J, Bollepalli S, Buchwald J, Iso-Markku P, Korhonen T, Kovanen V, Kujala U,
- 555 Laakkonen EK, Latvala A, Leskinen T, et al. The Older Finnish Twin Cohort - 45 Years
- 556 of Follow-up. Twin Res. Hum. Genet. 2019;22:240–254.
- 557 15. Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, Reeve MP,
- 558 Laivuori H, Aavikko M, Kaunisto MA, et al. FinnGen provides genetic insights from a
- 559 well-phenotyped isolated population. *Nature*. 2023;613:508–518.
- 560 16. Krokstad S, Sund ER, Kvaløy K, Rangul V, Næss M. HUNT for better public health.
- 561 Scand. J. Public Health. 2022;50:968-971.
- 562 17. Sollis E, Mosaku A, Abid A, Buniello A, Cerezo M, Gil L, Groza T, Güneş O, Hall P,
- 563 Hayhurst J, et al. The NHGRI-EBI GWAS Catalog: knowledgebase and deposition
- 564 resource. Nucleic Acids Res. 2023;51:D977-D985.
- 565 18. Piirtola M, Kaprio J, Ropponen A. A Study of Sedentary Behaviour in the Older Finnish
- 566 Twin Cohort: A Cross Sectional Analysis. *BioMed Res. Int.* 2014;2014:1–9.
- 567 Wang Z, Emmerich A, Pillon NJ, Moore T, Hemerich D, Cornelis MC, Mazzaferro E,
- 568 Broos S, Ahluwalia TS, Bartz TM, et al. Genome-wide association analyses of physical
- 569 activity and sedentary behavior provide insights into underlying mechanisms and roles
- 570 in disease prevention. Nat. Genet. 2022;54:1332–1344.
- 571 Schizophrenia Working Group of the Psychiatric Genomics Consortium, Bulik-Sullivan
- 572 BK, Loh P-R, Finucane HK, Ripke S, Yang J, Patterson N, Daly MJ, Price AL, Neale
- 573 BM. LD Score regression distinguishes confounding from polygenicity in genome-wide
- 574 association studies. Nat. Genet. 2015;47:291-295.
- 575 Lloyd-Jones LR, Zeng J, Sidorenko J, Yengo L, Moser G, Kemper KE, Wang H, Zheng
- 576 Z, Magi R, Esko T, et al. Improved polygenic prediction by Bayesian multiple
- 577 regression on summary statistics. Nat. Commun. 2019;10:5086.
- 578 22. Herranen P, Palviainen T, Rantanen T, Tiainen K, Viljanen A, Kaprio J, Sillanpää E. A
- 579 Polygenic Risk Score for Hand Grip Strength Predicts Muscle Strength and Proximal
- 580 and Distal Functional Outcomes among Older Women. Med. Sci. Sports Exerc.
- 581 2022;54:1889-1896.
- 582 23. The Haplotype Reference Consortium. A reference panel of 64,976 haplotypes for
- 583 genotype imputation. *Nat. Genet.* 2016;48:1279–1283.
- 584 24. Brumpton BM, Graham S, Surakka I, Skogholt AH, Løset M, Fritsche LG, Wolford B,
- 585 Zhou W, Nielsen JB, Holmen OL, et al. The HUNT study: A population-based cohort
- 586 for genetic research. Cell Genomics. 2022;2:100193.
- 587 25. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal
- 588 components analysis corrects for stratification in genome-wide association studies. Nat.
- 589 Genet. 2006;38:904-909.

- 590 26. Tynkkynen NP, Törmäkangas T, Palviainen T, Hyvärinen M, Klevjer M, Joensuu L,
- Kujala U, Kaprio J, Bye A, Sillanpää E. Associations of polygenic inheritance of
- 592 physical activity with aerobic fitness, cardiometabolic risk factors and diseases: the
- HUNT study. Eur. J. Epidemiol. [Internet]. 2023 [cited 2023 Aug 22]; Available from:
- 594 https://link.springer.com/10.1007/s10654-023-01029-w
- 595 27. Joensuu L, Waller K, Kankaanpää A, Palviainen T, Kaprio J, Sillanpää E. Genetic
- Liability to Cardiovascular Disease, Physical Activity, and Mortality: Findings from the
- Finnish Twin Cohort. *Med. Sci. Sports Exerc.* [Internet]. 2024 [cited 2024 Jun
- 598 20]; Available from: https://journals.lww.com/10.1249/MSS.000000000003482
- 599 28. Tuomela J, Kaprio J, Sipilä PN, Silventoinen K, Wang X, Ollikainen M, Piirtola M.
- Accuracy of self-reported anthropometric measures Findings from the Finnish Twin
- 601 Study. Obes. Res. Clin. Pract. 2019;13:522–528.
- 602 29. Therneau T. survival: Survival Analysis. Version 3.5-8 [Internet]. [cited 2024 Feb
- 603 14]; Available from: https://cran.r-project.org/web/packages/survival/index.html
- 604 30. Alboukadel K, Marcin K, Przemyslaw B, Scheipl F. survminer: Drawing Survival
- 605 Curves using "ggplot2". Version 0.4.9. [Internet]. [cited 2024 Feb 14]; Available from:
- 606 https://cran.r-project.org/web/packages/survminer/index.html
- 31. Vaura F, Kauko A, Suvila K, Havulinna AS, Mars N, Salomaa V, FinnGen, Cheng S,
- Niiranen T. Polygenic Risk Scores Predict Hypertension Onset and Cardiovascular
- 609 Risk. *Hypertension*. 2021;77:1119–1127.
- 610 32. Pace M, Cayotte E, Agafitei L, Zupanic T, Wojtyniak B, Gissler M, Lanzieri G,
- 611 Glickman M, Grande E. Revision of the European Standard Population: report of
- Eurostat's task force: 2013 edition. 2013 ed. Luxembourg: Publications Office; 2013.
- 613 33. Competing Risks Cumulative Incidence [Internet]. Tidycmprsk 100. [cited 2024 Jun
- 614 6]; Available from: https://mskcc-epi-bio.github.io/tidycmprsk/reference/cuminc.html
- 615 34. VanderWeele TJ. Causal Mediation Analysis With Survival Data. *Epidemiology*.
- 616 2011;22:582–585.
- 617 35. Speakman JR. An Evolutionary Perspective on Sedentary Behavior. *BioEssays*.
- 618 2020;42:1900156.
- 36. Van De Vegte YJ, Said MA, Rienstra M, Van Der Harst P, Verweij N. Genome-wide
- association studies and Mendelian randomization analyses for leisure sedentary
- 621 behaviours. Nat. Commun. 2020;11:1770.
- 622 37. The Human Protein Atlas: DLG4 [Internet]. [cited 2023 Oct 31]; Available from:
- https://www.proteinatlas.org/ENSG00000132535-DLG4
- 38. Wahid A, Manek N, Nichols M, Kelly P, Foster C, Webster P, Kaur A, Friedemann
- Smith C, Wilkins E, Rayner M, et al. Quantifying the Association Between Physical
- Activity and Cardiovascular Disease and Diabetes: A Systematic Review and Meta-
- 627 Analysis. J. Am. Heart Assoc. 2016;5:e002495.

- 628 39. Bauman AE, Reis RS, Sallis JF, Wells JC, Loos RJ, Martin BW. Correlates of physical
- activity: why are some people physically active and others not? *The Lancet*.
- 630 2012;380:258–271.
- 631 40. Lieberman DE. Is Exercise Really Medicine? An Evolutionary Perspective: *Curr*.
- 632 Sports Med. Rep. 2015;14:313–319.
- 633 41. Eaton SB, Eaton SB. An evolutionary perspective on human physical activity:
- implications for health. Comp. Biochem. Physiol. A. Mol. Integr. Physiol.
- 635 2003;136:153–159.
- 42. Kujala UM, Palviainen T, Pesonen P, Waller K, Sillanpää E, Niemelä M, Kangas M,
- Vähä-Ypyä H, Sievänen H, Korpelainen R, et al. Polygenic Risk Scores and Physical
- 638 Activity. *Med. Sci. Sports Exerc.* 2020;52:1518–1524.
- 639 43. Hoed MD, Brage S, Zhao JH, Westgate K, Nessa A, Ekelund U, Spector TD, Wareham
- NJ, Loos RJ. Heritability of objectively assessed daily physical activity and sedentary
- 641 behavior. Am. J. Clin. Nutr. 2013;98:1317–1325.
- 44. Van Der Aa N, Bartels M, Te Velde SJ, Boomsma DI, De Geus EJC, Brug J. Genetic
- and Environmental Influences on Individual Differences in Sedentary Behavior During
- Adolescence: A Twin-Family Study. Arch. Pediatr. Adolesc. Med. [Internet]. 2012
- 645 [cited 2023 Oct 30];166. Available from:
- http://archpedi.jamanetwork.com/article.aspx?doi=10.1001/archpediatrics.2011.1658
- 45. Nelson MC, Gordon-Larsen P, North KE, Adair LS. Body Mass Index Gain, Fast Food,
- and Physical Activity: Effects of Shared Environments over Time\*. *Obesity*.
- 649 2006;14:701–709.
- 46. Muñoz M, Pong-Wong R, Canela-Xandri O, Rawlik K, Haley CS, Tenesa A. Evaluating
- the contribution of genetics and familial shared environment to common disease using
- 652 the UK Biobank. *Nat. Genet.* 2016;48:980–983.
- 47. Young AI. Solving the missing heritability problem. *PLOS Genet*. 2019;15:e1008222.
- 48. Jang S-K, Evans L, Fialkowski A, Arnett DK, Ashley-Koch AE, Barnes KC, Becker
- DM, Bis JC, Blangero J, Bleecker ER, et al. Rare genetic variants explain missing
- heritability in smoking. *Nat. Hum. Behav.* 2022;6:1577–1586.
- 49. Wainschtein P, Jain D, Zheng Z, TOPMed Anthropometry Working Group, Aslibekyan
- S, Becker D, Bi W, Brody J, Carlson JC, Correa A, et al. Assessing the contribution of
- rare variants to complex trait heritability from whole-genome sequence data. *Nat. Genet.*
- 660 2022;54:263–273.
- 661 50. Choi BCK, Pak AWP. A catalog of biases in questionnaires. Prev. Chronic. Dis.
- 662 2005;2:A13.

## **Table**

Table 1. Descriptives of individuals with any CVD in the main FinnGen cohort and in the replication cohort (HUNT).

Characteristic	Main cohort			Replication cohort	
	$\mathbf{N}$	FinnGen	$\mathbf{N}$	HUNT	
Age (years)	293,250	67.0 (13.0)	35,289	64.0 (13.1)	
Female (%)	293,250	52.3	18,218	51.6	
BMI $(kg/m^2)$	82,224	27.8 (5.3)	22,398	27.9 (4.5)	
Smoking status	48,391		21,768		
Never (%)	17,915	37.0	7,921	36.4	
Former (%)	7,248	15.0	8,607	39.5	
Current (%)	23,228	48.0	5,240	24.1	

Values are presented as means (standard deviation) for continuous variables and percentages for others. Age is from the end of follow-up, and others the last known information during adulthood; BMI, body mass index; FinnGen data is from FinnGen data release 11.


Figure legends

670

673

680

- Figure 1. Study design and cohorts. PGS LST, polygenic score for leisure screentime; CVD, cardiovascular disease
- Figure 2. Associations between polygenic score for leisure screen time and cardiovascular disease incidence. Values are hazard ratios (HRs) and 95% confidence intervals (CIs) per one standard deviation increase in the polygenic score for leisure screen time. We used age as the time scale, and the first ten principal components of ancestry, sex, and genotyping batch as covariates; CVD, cardiovascular disease. Incidence values are age-standardized according to the European Standard Population to enable comparison between FinnGen and HUNT cohorts.
- Figure 3. Cumulative incidence curves for high (> 90<sup>th</sup> percentile [red]) and low (< 10<sup>th</sup> percentile [blue]) PGS LST groups in the FinnGen cohort based on Cox proportional hazard models and adjusted for the first ten principal components, sex, and genotyping batch.



Cardiovascular disease	Cases/N	Incidence/10,000 person-years			HR (95% CI)	
Any CVD			1			
FinnGen	168,770/293,250	34.9		٠	1.05 (1.05 to 1.06)	
HUNT	30,369/35,289	36.5		-	1.05 (1.03 to 1.06)	
Hypertensive diseases						
FinnGen	108,040/322,890	20.5		•	1.09 (1.08 to 1.09)	
HUNT	14,939/36,331	17.5		-	1.08 (1.06 to 1.09)	
Ischemic heart diseases						
FinnGen	64,724/333,012	12.0		•	1.06 (1.05 to 1.07)	
HUNT	11,204/36,378	13.6		-	1.07 (1.05 to 1.09)	
Cerebrovascular disease	s					
FinnGen	34,170/332,730	6.1		•	1.05 (1.04 to 1.06)	
HUNT	6,222/36,389	6.3	i	-	1.04 (1.01 to 1.06)	
		0.8	3 0.9 1	1.1	1.2	
		Lower risk Higher risk				

